- Home
- JYD vs NRSN Comparison
JYD vs NRSN Comparison
Compare JYD & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | NRSN |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JYD | NRSN |
|---|---|---|
| Price | $0.93 | $3.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $97.33 |
| AVG Volume (30 Days) | ★ 41.1K | 17.6K |
| Earning Date | 10-23-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.25 |
| 52 Week High | $6.85 | $7.50 |
Technical Indicators
Market Signals| Indicator | JYD | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 44.05 |
| Support Level | $0.65 | $0.63 |
| Resistance Level | $1.06 | $7.50 |
| Average True Range (ATR) | 0.09 | 0.62 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 61.10 | 1.61 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.